Post Profile






U.S. tribal patent deal could have big impact on generic drug market

(Reuters) - A groundbreaking deal between Allergan Plc and a Native American tribe to shield the company's patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts said, potentially dealing a blow to generic competition.
read more

share
See more about: Allergan Plc

Related Posts


Allergan, Argentum settle patent dispute over eye drug Restasis

Health : Reuters: Health

(Reuters) - U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis.

Allergan pays Mohawk Tribe to protect patents from challenges

Health : Reuters: Health

(Reuters) - Allergan Plc will transfer to the Saint Regis Mohawk Tribe rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges.

Mylan says Allergan misusing tribal sovereignty in patent dispute

Health : Reuters: Health

NEW YORK (Reuters) - Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.

Tech entity has tribal patent deal similar to Allergan's

Health : Reuters: Health

(Reuters) - The Native American tribe that agreed to hold patents for the drug company Allergan Plc in an attempt to shield them from U.S. administrative review is also doing so for a technology firm.

Challenge of Allergan tribal patent deal in uncharted legal territory

Health : Reuters: Health

(Reuters) - As generic drug manufacturers are gearing up to argue that a deal Allergan Plc made with a Native American tribe to shield patents from administrative review is a sham, some experts say the generic companies are in uncha...

Comments


Copyright © 2016 Regator, LLC